CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 178 enrolled
Drug / intervention
KAD-1229 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02154347
NCT02154347Phase 4Completed
CompareCT.gov

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Jun 3, 2014·Updated Sep 6, 2019

In Brief

A Phase 4 clinical trial evaluating KAD-1229, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 178 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 3, 2014
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Posted 12.1 years ago

Interventions

KAD-1229drug

Placebodrug

Insulindrug